Portopulmonary hypertension in the current era of pulmonary hypertension management
Laurent Savale,Manuel Guimas,Nathan Ebstein,Marie Fertin,Mitja Jevnikar,Sébastien Renard,Delphine Horeau-Langlard,Cécile Tromeur,Céline Chabanne,Grégoire Prevot,Ari Chaouat,Pamela Moceri,Élise Artaud-Macari,Bruno Degano,Romain Tresorier,Clément Boissin,Hélène Bouvaist,Anne-Claire Simon,Marianne Riou,Nicolas Favrolt,Sylvain Palat,Delphine Bourlier,Pascal Magro,Vincent Cottin,Emmanuel Bergot,Nicolas Lamblin,Xavier Jaïs,Audrey Coilly,François Durand,Claire Francoz,Filomena Conti,Philippe Hervé,Gérald Simonneau,David Montani,Jean-Charles Duclos-Vallée,Didier Samuel,Marc Humbert,Pascal De Groote,Olivier Sitbon
DOI: https://doi.org/10.1016/j.jhep.2020.02.021
Abstract:Background & aims: Long-term outcomes in portopulmonary hypertension (PoPH) are poorly studied in the current era of pulmonary hypertension management. We analysed the effect of pulmonary arterial hypertension (PAH)-targeted therapies, survival and predictors of death in a large contemporary cohort of patients with PoPH. Methods: Data from patients with PoPH consecutively enrolled in the French Pulmonary Hypertension Registry between 2007 and 2017 were collected. The effect of initial treatment strategies on functional class, exercise capacity and cardiopulmonary haemodynamics were analysed. Survival and its association with PAH- and hepatic-related characteristics were also examined. Results: Six hundred and thirty-seven patients (mean age 55 ± 10 years; 58% male) were included. Fifty-seven percent had mild cirrhosis, i.e. Child-Pugh stage A. The median model for end-stage liver disease (MELD) score was 11 (IQR 9-15). Most patients (n = 474; 74%) were initiated on monotherapy, either with a phosphodiesterase-5 inhibitor (n = 336) or with an endothelin-receptor antagonist (n = 128); 95 (15%) were initiated on double oral combination therapy and 5 (1%) on triple therapy. After a median treatment time of 4.5 months, there were significant improvements in functional class (p <0.001), 6-minute walk distance (6MWD) (p <0.0001) and pulmonary vascular resistance (p <0.0001). Overall survival rates were 84%, 69% and 51% at 1, 3 and 5 years, respectively. Baseline 6MWD, sex, age and MELD score or Child-Pugh stage were identified as independent prognostic factors. Survival from PoPH diagnosis was significantly better in the subgroup of patients who underwent liver transplantation (92%, 83% and 81% at 1, 3 and 5 years, respectively). Conclusion: Survival of patients with PoPH is strongly associated with the severity of liver disease. Patients who underwent liver transplantation had the best long-term outcomes. Lay summary: Portopulmonary hypertension is defined by the presence of pulmonary arterial hypertension in the context of chronic liver disease and is characterized by progressive shortness of breath and exercise limitation. The presence of severe pulmonary arterial hypertension in liver transplant candidates represents a contraindication for such a surgery; however, treatments targeting pulmonary arterial hypertension are efficacious, allowing for safe transplantation and conferring good survival outcomes in those who undergo liver transplantation.